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Abstract
Background: To identify the differential tuberculosis (TB) characteristics within the immigrant population with respect to
natives in Spain.
Methodology/Principal Findings: A prospective cohort study design was implemented to examine the TB cases diagnosed
and starting standard antituberculous treatment in Spain, between January 1st 2006 and March 31st 2007. A logistic
regression analysis was performed to determine differential characteristics. 1,490 patients were included in the study
population, 1,048 natives and 442 (29.7%) immigrants. According to the multivariate analysis, the following variables were
significantly associated with immigrant TB cases: younger age (OR=3.79; CI:2.16–6.62), living in group situation (OR=7.61;
CI:3.38–12.12), lower frequency of disabled (OR:0.08; CI:0.02–0.26) and retired (OR:0.21; CI:0.09–0.48) employment status,
lower frequency of pulmonary disease presentation (OR=0.47; CI:0.24–0.92), primary or emergency care admission
(OR=1.80; CI:1.05–3.06 and OR=2.16; CI:1.36–3.45), drug resistance (OR=1.86; CI:1.01–3.46), treatment default (OR:2.12;
CI:1.18–3.81), lower frequency of alcohol and cigarette consumption (OR=2.10; CI:1.42–3.11 and OR=2.85; CI:2.10–3.87
respectively), more directly observed treatment (OR=1.68; CI:1.04–2.69), and poor understanding of TB disease and its
treatment (OR=3.11; CI:1.86–5.20). The low percentage of primary MDR-TB in the native population (0.1% vs. 2.2% of
immigrants) should be noted.
Conclusions/Significance: The differences show the need to introduce specific strategies in the management of TB within
the immigrant population, including the improvement of social and work conditions.
Citation: Garcı ´a-Garcı ´a J-M, Blanquer R, Rodrigo T, Cayla ` JA, Caminero JA, et al. (2011) Social, Clinical and Microbiological Differential Characteristics of
Tuberculosis among Immigrants in Spain. PLoS ONE 6(1): e16272. doi:10.1371/journal.pone.0016272
Editor: Pere-Joan Cardona, Fundacio ´ Institut Germans Trias i Pujol; Universitat Auto `noma de Barcelona CibeRES, Spain
Received October 10, 2010; Accepted December 10, 2010; Published January 20, 2011
Copyright:  2011 Garcı ´a-Garcı ´a et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was funded by the SEPAR PII TB (Integrated Investigation Programme in Tuberculosis of the Spanish Respiratory and Thoracic Surgery
Society). (www.separ.es.) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: josemaria.garciag@sespa.princast.es
" Membership of the Working Group on Completion of Tuberculosis Treatment in Spain is provided in the Acknowledgments.
Introduction
The World Health Organization (WHO) estimated a tubercu-
losis (TB) annual incidence of 9.4 million cases (139/100,000
inhabitants) in 2008, of which 57% of pulmonary cases were
smear-positive, 15% were co-infected with HIV and 11% were
cases of multi-drug resistant TB (MDR-TB), defined as resistance
to at least isoniazid and rifampin [1].
The global TB prevalence has progressively decreased in high-
income countries, however HIV co-infection, immigration from
high TB burden countries for economic reasons, MDR-TB and
overcrowding within poor communities of large cities have
hindered further decline. The decrease in TB rates began to
taper in many industrialized countries and TB rates in some even
started to increase in the early 1990s. However, incidence among
the native population continued to decrease, resulting in a higher
proportion of foreign-born cases. This trend has been documented
in European countries such as Denmark, Holland, Sweden, the
United Kingdom and Switzerland, where foreign-born cases
comprise more than half of TB cases, with incidences such as 100/
100,000 among immigrants versus 15/100,000 among the native
population [2].
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16272MDR-TB is a growing problem worldwide [3]. In 2008, an
estimated 390.000 to 510,000 cases of MDR-TB emerged globally.
Among all global incident TB cases, 3.6% are believed to have
MDR-TB. Almost 50% of MDR-TB cases worldwide are
estimated to occur in China and India, and another 7% in Russia
and the former Soviet countries [4]. Immigrants in Europe may be
from these and other high MDR-TB burden countries. The
prevalence of MDR-TB among new TB cases ranged from 0% in
some countries to 22.3% [3,5]. In 2008, MDR-TB caused an
estimated 150,000 deaths [4]. The global expenditure in the
diagnosis and treatment of MDR-TB and extensively drug-
resistant TB (XDR-TB), defined as MDR-TB plus resistance to
fluroquinolones and at least one second-line injectable drug, were
estimated at 700 million US dollars (USD) for 2009 and the cost of
treatment for a MDR-TB case is estimated at 10,000USD versus
100USD for a drug-susceptible TB case [6].
A study performed in Spain by the Integrated Investigation
Programme in TB (PII TB) of the Spanish Respiratory and
Thoracic Surgery Society (SEPAR) showed a considerable
increase in foreign-born TB cases, reaching 30% of the total cases
[7]. In Barcelona, a Spanish city which has experienced a constant
influx of immigrants, the percentage of foreign-born cases
increased from 5% to 50% between 1995 and 2008 [8].
The objective of this study was to determine the differential
social, clinical and microbiological characteristics between native
and immigrant cases for the implementation of stricter control
measures during treatment follow-up to monitor treatment
completion among this group of patients.
Methods
Participants and description of procedures
This multi-center prospective cohort study of TB cases was
supported by 61 collaborators, mainly respiratory and infectious
disease physicians, from 53 health centers in the different regions
of Spain. The study population included a cohort of TB patients of
18 years of age or older diagnosed between January 1
st 2006 and
March 31
st 2007, who started standard anti-TB treatment with
rifampin and isoniazid during 6 months, and pyrazinamide with
ethambutol (defined as four drugs) or without ethambutol (defined
as three drugs) for the first two months. Patients with known
previous drug resistance or those for whom standard anti-TB
treatment was contraindicated were excluded. Study data included
socio-demographic information (patients born outside of Spain
were assumed to have moved mainly for economic reasons),
smoking (including smokers of one or more cigarettes per day and
ex-smokers), drug and alcohol habits (men consuming over 280 g
of alcohol per week, and women over 168 g, were considered
alcoholics). Users of intravenous heroin and/or cocaine were
classified as intravenous drug users (IVDU), anthropometrics,
clinical history, diagnostic methods, drug susceptibility testing and
results, anti-TB treatment, clinical response, and treatment
adherence and outcome. This information was collected using
electronic case reports which were available to collaborating
investigators on the SEPAR website. All cases were followed
according to an evaluation schedule (Table 1).
Ethics Statement
In accordance with the International Directory for Ethical
Revision of Epidemiological Studies (Council for the International
Organizations of Medical Sciences - CIOMS, Geneva, 1991) and
the Spanish Epidemiology Society recommendations on ethical
aspects of epidemiological research, this study was submitted to the
Teknon Medical Center Investigation Ethical Committee in
Barcelona for evaluation. Verbal informed consent was obtained
for patient participation. All registries with patient identification
information were handled in a confidential manner and in
accordance with the Spanish Law 15/1999 on the Protection of
Personal Character Data.
Statistical methods
A descriptive study was carried out on qualitative and
quantitative variables to characterize the study population.
Quantitative data are shown as medians and interquartile ranges
and qualitative data as a percentage. Proportions were compared
between groups using 62 tests, and when pertinent, the two-sided
Fisher test. The Mann-Whitney U test was used to compare the
values of diagnostic delay. Association was determined by odds ratio
(OR) and their 95% confidence intervals (CI). The association of
TB characteristics with the native or immigrant populations was
Table 1. Patient evaluation calendar.
Visit 1
Diagnosis
Visit 2
2 Months
Visit 3
6 Months
Visit 4
*
9,12,18 Months
(Optional)
Inclusion/Exclusion criteria X
Socio-demographic data X
Smoking/alcohol habits X
Anthropometrics XX X X
Clinical history X
Diagnostic methods X
Drug treatment XX X X
Clinical response XX X
Treatment adherence XX X
Sputum sample collection XX X X
Drug susceptibility testing X
Treatment outcome XX
*If treatment is continued for more than 6 months.
doi:10.1371/journal.pone.0016272.t001
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associated on a bivariate level. The test of Hosmer and Lemeshow
was used to check the goodness-of-fit of the model. A p-value of
,0.05 was considered significant. All of the analyses were
completed using SPSS Statistical Package, version 13.0 (SPSS
Inc, Chicago, IL, USA).
Results
Of the 1,500 patients enrolled during the study period, 10 were
excluded because they did not satisfy inclusion criteria and the
final total of analyzed cases was 1,490. Four hundred forty-two
(29.7%) were immigrants from 48 countries; the largest propor-
tions were from Romania (13.9%), Bolivia (13.5%), Morocco
(11.5%), Pakistan (9.5%), Ecuador (7.5%), Senegal (4.6%),
Colombia (4.4%), and Peru (4.4%).
In a bivariate analysis, the following TB characteristics were
significantly associated with immigrant TB cases: lower frequency
of disabled and retired employment status, pulmonary disease
presentation, alcohol consumption, smokers. However the follow-
ing characteristics were higher among immigrants: aged between
18–30 or 31–50 years, unemployment, living in group situation,
primary care or emergency care admission (instead of specialized
care), treatment with 4 drugs, drug resistance, treatment default,
directly observed treatment (DOT) implementation, and poor
understanding of TB disease and its treatment according to the
perception of the doctor in charge of the patient. There were no
statistically significant differences in sex, previous TB treatment,
injection drug use (IDU), diagnostic tests performed, HIV
infection, or diagnostic delay (Table 2).
According to the multivariate analysis, the following variables
were significantly associated with immigrant TB cases compared
to native cases: lower frequency of disabled and retired
employment status, alcohol and cigarette consumption, pulmonary
disease presentation, and higher frequency of age between 18–30
or 31–50 years, a group living situation, primary or emergency
care admission, drug resistance, treatment default, DOT and poor
understanding of TB disease and its treatment (Table 3). The
highest odds ratios were calculated for living in group situation,
aged between 18–30 years or 31–50 years and for poor
understanding of TB disease and its treatment. A higher rate of
successful treatment outcome using standard treatment was found
within the native population than among immigrants (91.9% of
natives and 83.5% of immigrants) (Table 4). Similarly, treatment
default was higher within the immigrant population.
Drug susceptibility was analyzed in 1,046 patients (70.2%), of
whom 745 were natives and 301 were immigrants. Of the 959
patients who had never previously received TB treatment, 682
were natives and 277 were immigrants. The low percentage of
primary MDR-TB in the native population (0.1%vs 2.2% of
immigrants) and the absence of mono-resistance to rifampin in
both groups of patients should be noted. Differences between
global percentages of drug resistance (18.3% of immigrants vs.
7.9% of native cases) and primary drug resistance (16.6% vs.
6.6%, respectively) were statistically significant (p,0.001 for both),
as well as for rates of MDR TB (Table 5). Drug susceptibility
testing to fluoroquinolones and second-line injectable drugs was
not performed routinely; so it was performed in few patients of our
study population. Six patients presented criteria for XDR-TB, 2
among native cases and 4 among immigrant cases.
Discussion
This multi-center study of TB diagnosed patients who started
standard anti-TB treatment resulted in a considerable percentage
of the foreign-born cases (29.7%) and demonstrated that particular
characteristic differences, personal, social as well as concerning
treatment follow-up and drug resistance, exist when compared to
native TB cases.
With respect to TB characteristics among the immigrant and
native populations, two recent publications did not find significant
differences of TB clinical presentation or risk factors, including
HIV co-infection [9,10]. The studies also showed that undocu-
mented immigrants have a larger diagnostic delay and present
more severe symptoms and advanced disease, even when no
statistically significant differences existed between the native and
documented immigrant populations. According to the authors, all
recently arriving immigrants should been screened, despite
absence of symptoms [9,10]. Study results from Spain are
somewhat heterogeneous and most discuss immigrant TB case
characteristics only. Some mention higher prevalence of HIV co-
infection [11,12] or higher latent TB infection rates [13], while
others vary in the predominant clinical forms of TB [11,12,14],
rates of drug resistance [13], or the proportion of lost to follow-up
cases [15].
A significant difference in age existed in our study between
immigrant cases, who were mainly under 50 years old, and native
cases, who were predominantly older. These results are consistent
with local and international publications [11,16,17] and parallel
the demographic characteristics of the total immigrant population.
Given the recent influx of immigrants to Spain and the young age
of those who migrate most of them for economical reasons, this
age difference between immigrant and native TB cases is logical. A
group living situation was also more frequent among immigrants
due to poor economical circumstances and is also a documented
risk factor for TB transmission [18]. We also found that immigrant
TB cases were admitted to emergency care more than native cases;
although the health system in Spain is universal this type of service
is more accessible than a specialist clinic (where an appointment is
necessary) to persons with frequent address changes or an
undocumented legal status, both common characteristics in the
foreign-born population. A similar result was observed in a study
carried out in Madrid [11]. Immigrant TB cases also had lower
average cigarette and alcohol consumption than their native
counterparts, as shown in Switzerland as well [9]. We think that
social and religious customs, as well as poor economical status
within the immigrant population, could have contributed to their
low consumption. Immigrant TB cases also had more difficulty
understanding TB disease and treatment, most likely for language,
social, and economical reasons. TB Programs should be adapted
to migration changes [18]. The use of community health workers,
who play the role of translators and culture mediators, has been
demonstrated as useful to minimize this problem [19].
Regarding treatment follow-up and final outcome, the native
population has a higher proportion of successful treatment
completion (cured patients plus those who complete treatment)
than the foreign-born population, even though successful treat-
ment completion was high in both groups (91.9% of natives and
83.5% of immigrants but in this group is lower than the
recommendation of more than 85%). Treatment default was also
more frequent among the immigrant population, though it was not
considered high (8.4%). Given these findings [13,20], control
measures, such as the use of DOT [13,21], more exhaustive
clinical follow-up with more visits, better communication between
healthcare professionals in different regions to locate transfer-out
and lost to follow-up patients, and continued efforts to integrate
and assimilate this population should be reinforced.
Drug susceptibility data was available in 70.2% of the study
population because only some collaborating centers could
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VARIABLES
Native
N( % )
Immigrant
N (%) p value OR 95% CI
SEX Male
Female
663 (64.7)
362 (35.3)
257(60.2)
170 (39.8)
0.105 0.82
1
0.65 – 1.04
AGE (YEARS) 18–30
31–50
.50
285 (27.2)
395 (37.7)
368 (35.1)
212 (48.0)
201 (45.5)
29 (6.6)
,0.001
,0.001
9.43
6.45
1
6.21 – 14.33
4.26 – 9.7
EMPLOYMENT Employed
Disabled
1
Unemployed
Retired
Unknown
591(56.4)
64 (6.1)
152 (14.5)
210 (20.0)
31 (3.0)
310 (70.1)
4 (0.9)
105 (23.8)
10 (2.3)
13 (2.9)
,0.001
0.058
,0.001
0.508
1
0.11
1.31
0.09
0.79
0.04 – 0.33
0.99 – 1.75
0.04 – 0.17
0.41 – 1.55
LIVING SITUATION Alone
Homeless or incarcerated
Group
2
Family
Unknown
128 (12.2)
33 (3.1)
36 (3.4)
835 (79.7)
16 (1.5)
29 (6.7)
21 (4.8)
153 (34.6)
227 (51.4)
12 (2.7)
0.003
,0.001
0.003
0.728
0.35
1
6.67
0.42
1.17
0.18 – 0.70
3.46 – 12.87
0.24 – 0.75
0.46 – 2.97
CLINICAL CENTER Primary care
Emergency care
Unknown
Specialist
185 (17.7)
445 (42.5)
245 (23.4)
173 (16.5)
83 (18.8)
237 (53.6)
85 (19.2)
37 (8.4)
0.001
,0.001
0.028
2.09
2.49
1.62
1
1.35 – 3.25
1.68 – 3.67
1.05 – 2.49
PREVIOUS TREATMENT No
Yes
Unknown
929 (88.6)
92 (8.8)
27 (2.6)
391 (88.5)
39 (8.8)
12 (2.7)
0.971
0.905
0.99
1
1.04
0.67 – 1.47
0.48 – 2.27
IDU
3 No
Unknown
Yes
616 (58.8)
416 (39.7)
16 (1.5)
256 (57.9)
181 (41.0)
5 (1.1)
0.582
0.524
1.33
1.39
1
0.48 – 3.66
0.502 – 3.85
DIAGNOSTIC METHODS Smear (+)
Smear (2)/Culture. (+)
Smear (2)/Culture (2)
Others
611 (58.3)
258 (24.6)
128 (12.2)
51 (4.9)
265 (60.0)
76 (17.2)
76(17.2)
25 (5.7)
0.631
0.066
0.500
0.885
0.601
1.21
1
0.53–1.45
0.34–1.03
0.69–2.11
SITE OF TUBERCULOSIS Extra-pulmonary
Mixed
Pulmonary
Unknown
99 (9.4)
40 (3.8)
899 (85.8)
10 (1.0)
60 (13.6)
27 (6.1)
350 (79.2)
5 (1.1)
0.718
0.032
0.618
0.89
1
0.57
0.74
0.50 – 1.61
0.34 – 0.95
0.22 – 2.40
TREATMENT 3D r u g s
4D r u g s
Unknown
698 (66.6)
316 (30.2)
34 (3.2)
72 (16.3)
333 (75.3)
37 (8.4)
,0.001
,0.001
1
10.21
10.55
7.66 – 13.61
6.24 – 17.83
DRUG SUSCEPTIBILITY Susceptible
Resistant
4
Unknown
801(76.4)
40 (3.8)
207 (19.8)
318 (71.9)
31 (7.0)
93 (21.0)
0.007
0.382
1
1.95
1.13
1.20 – 3.17
0.85 – 1.49
TREATMENT DEFAULT No
Yes
Unknown
963 (91.9)
41 (3.9)
44 (4.2)
369 (83.5)
51 (11.5)
22 (5.0)
,0.001
0.321
1
3.24
1.30
2.11 –4.98
0.77 – 2.20
ALCOHOL CONSUMPTION No
Yes
Unknown
694 (66.2)
317 (30.2)
37 (3.5)
370 (83.7)
58 (13.1)
14 (3.2)
,0.001
0.035
2.91
1
2.06
2.14 – 3.96
1.05 – 4.06
SMOKING
5 No
Yes
Unknown
406 (38.7)
630 (60.1)
12 (1.1)
270 (61.1)
167 (37.8)
5 (1.1)
,0.001
0.402
2.50
1
1.57
1.99 – 3.15
0.54 – 4.52
HIV INFECTION No
Yes
Unknown
717 (68.4)
47 (4.5)
284 (27.1)
343 (77.6)
19 (4.3)
80 (18.1)
0.547
0.228
1.18
1
0.69
0.68 –2.04
0.38 – 1.25
DOT
6 No
Yes
956 (91.2)
92 (8.8)
382 (86.4)
60 (13.6) ,0.001
1
1.63 1.15 –2.30
COMPRE-
HENSION
7
Well
Difficult
Unknown
928 (88.5)
74 (7.1)
46 (4.4)
338 (76.5)
65 (14.7)
39 (8.8)
,0.001
,0.001
1
2.41
2.32
1.69 – 3.44
1.49 – 3.63
DIAGNOSTIC DELAY
8 Days; median (IQR) 48 (24–92) 42 (21–91) 0,074
1Disabled: lacking one or more of the physical or mental abilities that most people have.
2Group living or living in a group: People of different families who live together in the same flat.
3IDU: Intravenous Drug Use.
4Resistant at least to one drug.
5In relation to tobacco: no (never smokers), yes (current or ex-smokers).
6DOT: Directly observed treatment.
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patients. However, the 1,046 patients with drug susceptibility
testing results available for first-line drugs available is large sample,
especially those 959 (682 natives and 277 immigrants) never
receiving anti-TB drugs in the past (defined as primary drug
resistance in this study). The inclusion criteria (only patients
receiving a standard six months regimen) could have introduced a
bias of the acquired resistance, because most of the patients who
had previously received anti-TB treatment were excluded. The
motive for this criteria was to determine the frequency of the use of
three or four drugs for standard treatment and the characteristics
of the patients taking these regimens. This bias is not a factor for
primary resistance because all new cases were included in the
study. Our results also reveal low primary MDR-TB resistance
(0.1%) in natives, as shown with other previous studies published
in Spain [13,22,23]. The primary MDR-TB rate is one of the
lowest of the world [4–6]. Free healthcare assistance offered by the
Spanish Health System and the widespread use of fixed-dose
combinations for more than 30 years could have contributed to
the low rate of drug resistance in Spain.
The percentage of any drug resistance (primary or acquired),
including MDR-TB, was higher among immigrants. This
Table 3. Tuberculosis characteristics in native and immigrants of Spain.
VARIABLES
Native
N( % )
Immigrant
N (%) p value OR 95% CI
AGE (YEARS) 18–30
31–50
.50
285 (27.2)
395 (37.7)
368 (35.1)
212 (48.0)
201 (45.5)
29 (6.6)
,0.001
,0.001
3.79
3.53
1
2.16–6.62
2.03–6.14
EMPLOYMENT Employed
Disabled
Unemployed
Retired
Unknown
591(56.4)
64 (6.1)
152 (14.5)
210 (20.0)
31 (3.0)
310 (70.1)
4 (0.9)
105 (23.8)
10 (2.3)
13 (2.9)
,0.001
0.683
,0.001
0.358
1
0.08
1.07
0.21
0.69
0.02–0.26
0.74–1.55
0.09–0.48
0.32–1.50
LIVING SITUATION Alone
Homeless or incarcerated
Group
Family
Unknown
128 (12.2)
33 (3.1)
36 (3.4)
835 (79.7)
16 (1.5)
29 (6.7)
21 (4.8)
153 (34.6)
227 (51.4)
12 (2.7)
0.324
,0.001
0.223
0.139
0.65
1
7.61
0.63
2.42
0.28–1.51
3.38–12.12
0.30–1.32
0.75–7.81
CLINICAL CENTER Primary care
Emergency care
Unknown
Specialist
185 (17.7)
445 (42.5)
245 (23.4)
173 (16.5)
83 (18.8)
237 (53.6)
85 (19.2)
37 (8.4)
0.030
0.001
0.126
1.80
2.16
1.50
1
1.05–3.06
1.36–3.45
0.89–2.54
SITE OF TUBERCULOSIS Extra-pulmonary
Mixed
Pulmonary
Unknown
99 (9.4)
40 (3.8)
899 (85.8)
10 (1.0)
60 (13.6)
27 (6.1)
350 (79.2)
5 (1.1)
0.700
0.027
0.108
0.86
1
0.47
0.26
0.39–1.85
0.24–0.92
0.05–1.33
DRUG SUSCEPTIBILITY Susceptible
Resistant
Unknown
801(76.4)
40 (3.8)
207 (19.8)
318 (71.9)
31 (7.0)
93 (21.0)
0.047
0.584
1
1.86
1.10
1.01–3.46
0.77–1.56
TREATMENT DEFAULT No
Yes
Unknown
963 (91.9)
41 (3.9)
44 (4.2)
369 (83.5)
51 (11.5)
22 (5.0)
0.012
0.376
1
2.12
1.40
1.18–3.81
0.66–2.97
ALCOHOL CONSUMPTIONNo
Yes
Unknown
694 (66.2)
317 (30.2)
37 (3.5)
370 (83.7)
58 (13.1)
14 (3.2)
,0.001
0.070
2.10
1
2.20
1.42–3.11
0.93–5.18
SMOKING No
Yes
1
Unknown
406 (38.7)
630 (60.1)
12 (1.1)
270 (61.1)
167 (37.8)
5 (1.1)
,0.001
0.370
2.85
1
1.79
2.10–3.87
0.49–6.47
DOT No
Yes
956 (91.2)
92 (8.8)
382 (86.4)
60 (13.6) 0.031
1
1.68 1.04–2.69
COMPRE-
HENSION
Well
Difficult
Unknown
928 (88.5)
74 (7.1)
46 (4.4)
338 (76.5)
65 (14.7)
39 (8.8)
,0.001
0.111
1
3.11
1.70
1.86–5.20
0.88–3.28
1Including ex smokers.
Cohort of 1,490 patients. Multivariate analysis.
doi:10.1371/journal.pone.0016272.t003
7Comprehension or understanding of TB: understanding of disease and its treatment according the perception of the doctor in charge of the patient.
8Diagnostic Delay: Median number of days between symptom onset and treatment initiation.
Cohort of 1,490 patients. Bivariate analysis.
doi:10.1371/journal.pone.0016272.t002
Table 2. Cont.
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primary, total, for rifampin, isoniazid and MDR-TB) except for
the acquired resistance, most likely because of the previously
mentioned bias. Differing patterns of primary resistance and that
of isoniazid have also been documented in other studies [13,16].
We also found a significant difference between the two populations
regarding MDR-TB prevalence, despite the low number of cases
in our population, as documented in other studies [16,17]. Initial
treatment using a four-drug regimen was most likely prescribed for
immigrant cases because of a consensus recommendation [21] and
our results support its continuation. Nonetheless, the difference in
treatment prescription between immigrant and native cases will
probably decrease because Spanish [24] and international TB
treatment guidelines [25] now recommend that all cases should be
initially treated with four drugs. The implementation of a
prospective study examining primary and acquired drug resistance
patterns is also necessary.
This study also provides two other interesting findings. The first
is the absence of mono-resistance to rifampin in Spain, where all
the strains with rifampin resistance were also resistant to at least
isoniazid (MDR-TB). This strongly supports the use of rifampin
resistance as a marker of MDR-TB [5]. Secondly, this study shows
that XDR-TB cases do exist in Spain among both immigrant and
native populations, despite the very low MDR-TB rate. Thus,
drug susceptibility testing to fluoroquinolones and second-line
injectables drugs should be performed systematically to all MDR-
TB patients.
In this study we can also deduce that social determinants of
health influences the epidemiological situation of TB among
immigrants. In order to achieve a situation of equity, in these
populations in Spain and in other countries with a high number of
immigrants due mainly to economic reasons, several public health
interventions are needed (favour their access to health system,
directly observed therapy in some cases, TB programs with
community health workers, etc) [21].
In conclusion, we have found that a considerable proportion of
TB cases in Spain are immigrants and that significant differences
exist between immigrant and native cases. We therefore reiterate
that work and social conditions must be improved for the foreign
community, as well as the availability of social workers and
community health workers who address comprehension issues.
Similarly, more exhaustive treatment follow-up efforts must be
made, including the use of DOT, additional clinical visits, and
more communication between healthcare professionals. Finally,
standard TB treatment should start with a four-drug regimen and
primary drug susceptibility testing should be preformed systemat-
ically to optimize treatment, stop further transmission, and above-
all, prevent the emergence of drug resistances.
Table 4. Treatment outcome distribution among native and
immigrant tuberculosis cases*.
TREATMENT
OUTCOME N NATIVE (%)
N IMMIGRANT
(%) N TOTAL (%)
Cured 583 (55.6) 209 (47.3) 792 (53.2)
Completed
treatment
380 (36.3) 160 (36.2) 540 (36.2)
Incomplete 1( 0.1)1 ( 0.2) 2 (0.1)
Transfer out 16 (1.5)1 7 ( 3.8) 33 (2.2)
Default 13 (1.2)1 4 ( 3.2) 27 (1.8)
Died 23 (2.3)4 ( 0.9) 27 (1.8)
Lost to follow-up 28 (2.7)3 7 ( 8.4) 65 (4.4)
Other 4( 0.4)0 ( 0.0) 4 (0.3)
TOTAL 1048 (100.0) 442 (100.0) 1490 (100.0)
*Successful treatment outcome is the sum of cured cases plus case of
completed treatment.
doi:10.1371/journal.pone.0016272.t004
Table 5. Distribution of drug resistance among native and immigrant tuberculosis patients with drug susceptibility testing
performed.
RESISTANCE
N NATIVE
N/total (%) N IMMIGRANT N/total (%) p value OR 95% CI
Global Total
Isoniazid
Rifampin
Pyrazinamide
Ethambutol
Streptomycin
MDR-TB
59/745 (7.9)
27/745 (3.6)
2/745 (0.3)
6/745 (0.8)
5/745 (0.7)
19/745 (2.6)
2/745 (0.3)
55/301 (18.3)
26/301 (8.6)
8/301 (2.7)
4/301 (1.3)
3/301 (1.0)
14/301 (4.7)
8/301 (2.7%)
,0.001
,0.001
0.001
0.817
0.871
0.162
0.001
2.60
2.5
10.14
10.14
1.72–3.93
1.39–4.54
1.99–69.50
1.99–69.50
Primary Total
Isoniazid
Rifampin
Pyrazinamide
Ethambutol
Streptomycin
MDR-TB
45/682 (6.6)
22/682 (3.2)
1/682 (0.1)
5/682 (0.7)
4/682 (0.6)
13/682 (1.9)
1/682 (0.1)
46/277 (16.6)
23/277 (8.3)
6/277 (2.2)
2/277 (0.7)
3/277 (1.1)
12/277 (4.3)
6/277 (2.2)
,0.001
,0.001
0.002
0.99
0.689
0.05
0.002
2.82
2.72
15.08
15.08
1.7 8–4.47
1.43–5.16
1.80–33.87
1.80–33.87
Acquired Total
Isoniazid
Rifampin
Pyrazinamide
Ethambutol
Streptomycin
MDR-TB
14/63 (22.2)
5/63 (7.9)
1/63 (1.6)
1/63 (1.6)
1/63 (1.5)
6/63 (9.5)
1/63 (1.6)
9/24 (37.5)
3/24 (12.5)
2/24(8.3)
2/24 (8.3)
0/24(0.0)
2/24 (8.3)
2/24 (8.3)
0.24
0.80
0.37
0.37
1
1
0.37
MDR: Drug resistance to at least isoniazid (H) and rifampin (R).
doi:10.1371/journal.pone.0016272.t005
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